SecBot SecBot
SECBOTREPLAY Home › Report › AKBA

AKBA · Akebia Therapeutics reported strong financial results for Q4 and…

Akebia Therapeutics, Inc. · 8-K filed Feb 26, 2026 at 07:04 ET

At the news

BULLISHIMPACT 7/10

8-K filed Feb 26, 2026 at 07:04 ET

Akebia Therapeutics reported strong financial results for Q4 and full-year 2025, with total revenues of $57.6 million (Q4) and $236.2 million (full-year), representing significant year-over-year growth. The increase was driven by Vafseo sales following its 2025 U.S. launch and higher Auryxia volumes. The company reported a reduced net loss and expects Vafseo revenue growth in 2026 due to expanded access and improved adherence, though Auryxia revenues are expected to decline due to generic competition.

  • Q4 2025 total revenues: $57.6 million (up from $46.5 million in Q4 2024)
  • Full-year 2025 total revenues: $236.2 million (up from $160.2 million in 2024)
  • Vafseo net product revenues: $6.2 million in Q4 2025 and $45.8 million for full-year 2025
  • Auryxia net product revenues: $48.1 million in Q4 2025 (up from $44.4 million in Q4 2024)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access